Most cited papers from Rotkreuzklinikum München

Rotkreuzklinikum München

What are the most cited papers from Rotkreuzklinikum München?

The most cited paper from Rotkreuzklinikum München is "Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy" (Carsten Denkert et al., 2017), with 2,205 citations. Next come "Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial" (1,048) and "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study" (714).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 51 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Carsten Denkert et al. · The Lancet Oncology	8 Dec 2017	2,205
2	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Gϋnter von Minckwitz et al. · The Lancet Oncology	30 Apr 2014	1,048
3	A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study S. Loibl et al. · Annals of Oncology Open access	7 May 2019	714
4	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Carsten Denkert et al. · The Lancet Oncology	9 Jul 2021	581
5	Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Michael Gnant, Brigitte Mlineritsch, Herbert Stoeger et al. · The Lancet Oncology	12 Jun 2011	474
6	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology	16 Jan 2012	459
7	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial Michael Untch et al. · The Lancet Oncology	8 Feb 2016	422
8	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Eric Hahnen et al. · JAMA Oncology Open access	17 Jul 2017	398
9	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study Klaus‐Peter Dieckmann et al. · Journal of Clinical Oncology Open access	15 Mar 2019	354
10	Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Gϋnter von Minckwitz et al. · Breast Cancer Research and Treatment Open access	2 Nov 2010	280
11	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer Anne Sophie V M van den Heerik et al. · International Journal of Gynecological Cancer Open access	12 Oct 2020	251
12	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo Thomas Karn et al. · Annals of Oncology Open access	24 May 2020	241
13	Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial Nadia Harbeck et al. · Nature Medicine Open access	13 Sep 2024	216
14	S3-Leitlinie zum exokrinen Pankreaskarzinom Thomas Theodor Werner Seufferlein et al. · Zeitschrift für Gastroenterologie Open access	11 Dec 2013	216
15	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy Sibylle Loibl, Berit Maria Müller, Gϋnter von Minckwitz et al. · Breast Cancer Research and Treatment	11 Aug 2011	211
16	Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years Bernd Hofmann, Michal Hlaváč, Ramón Salcedo Martínez et al. · Journal of neurosurgery	2008	207
17	Systematic review of hyperbaric oxygen in the management of chronic wounds Irmgard Roeckl-Wiedmann, Martin R. Bennett, Peter Kranke · British journal of surgery Review	2005	191
18	A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients Sherko Küemmel et al. · Annals of Surgery	4 Nov 2020	183
19	Theorie und Operationstechnik der Kapsulorhexis Th. Neuhann · Klinische Monatsblätter für Augenheilkunde	Jun 1987	173
20	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto Michael Untch et al. · Journal of Clinical Oncology	13 May 2019	162
21	Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) Bernhard Gerber, Sibylle Loibl, Holger Eidtmann et al. · Annals of Oncology Open access	18 Oct 2013	156
22	Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) Peter Andreas Fasching et al. · Annals of Oncology Open access	21 Oct 2020	147
23	Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) Gϋnter von Minckwitz et al. · Annals of Oncology Open access149 authors	16 Sep 2014	140
24	Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results Oleg Gluz et al. · JNCI Journal of the National Cancer Institute	13 Nov 2017	135
25	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials Sibylle Loibl, Christian Jackisch, Bianca Lederer et al. · Breast Cancer Research and Treatment	24 Jun 2015	127
26	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) C. Rieger, Blasius Janusch Liss, Sibylle C. Mellinghoff et al. · Annals of Oncology Open access	23 Apr 2018	126
27	Quality of Life and Patient Satisfaction Following Male-to-Female Sex Reassignment Surgery Nikolaos A. Papadopulos, Jean-Daniel Lellé, Dmitry Zavlin et al. · The Journal of Sexual Medicine	30 Mar 2017	126
28	Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials Caterina Fontanella et al. · Breast Cancer Research and Treatment	Feb 2015	125
29	Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial Sibylle Loibl et al. · Annals of Oncology Open access	3 Nov 2016	120
30	Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma Sibylle Loibl et al. · Breast Cancer Research and Treatment Open access	Feb 2014	119
31	Coexistent Primary Open-Angle Glaucoma and Cataract: Interim Analysis of a Trabecular Micro-Bypass Stent and Concurrent Cataract Surgery Detlev Spiegel, Wolfgang Wetzel, Thomas F. Neuhann et al. · European Journal of Ophthalmology	May 2009	119
32	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial Axel Bauer et al. · The Lancet Respiratory Medicine Open access114 authors	11 Jun 2021	105
33	Multicenter Double-Blinded Randomized Controlled Trial of Standard Abdominal Wound Edge Protection With Surgical Dressings Versus Coverage With a Sterile Circular Polyethylene Drape for Prevention of Surgical Site Infections André L. Mihaljević et al. · Annals of Surgery	7 Oct 2014	103
34	Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation Zhibo Gai, Michele Visentin, Ting Gui et al. · Molecular Pharmacology Open access	9 May 2018	91
35	De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial Ulrike Anneliese Nitz et al. · The Lancet Oncology	8 Apr 2022	90
36	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials Sonia Lorena Villegas et al. · European Journal of Cancer	18 Mar 2021	90
37	Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer Sherko Kuemmel et al. · JAMA Surgery Open access	7 Jun 2023	89
38	Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes Silvia Darb‐Esfahani, Gϋnter von Minckwitz, Carsten Denkert et al. · BMC Cancer Open access	28 Jul 2014	88
39	Body Image, Personality Traits, and Quality of Life in Botulinum Toxin A and Dermal Filler Patients Dagmar Scharschmidt, Ursula Mirastschijski, Simone Preiss et al. · Aesthetic Plastic Surgery	11 Jun 2018	87
40	Male-to-Female Sex Reassignment Surgery using the Combined Vaginoplasty Technique: Satisfaction of Transgender Patients with Aesthetic, Functional, and Sexual Outcomes Dmitry Zavlin, Jürgen Schaff, Jean-Daniel Lellé et al. · Aesthetic Plastic Surgery	3 Nov 2017	86
41	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro) Gϋnter von Minckwitz, Mahdi Rezai, Peter Andreas Fasching et al. · Annals of Oncology Open access	23 Nov 2013	80
42	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44) Jens Huober et al. · European Journal of Cancer	27 Mar 2013	79
43	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study Miguel Martín et al. · The Lancet Oncology	Apr 2011	77
44	Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Markus Ruhnke et al. · Mycoses Open access	Apr 2020	75
45	The Perioperative Care of Older Patients Cynthia Olotu, Arved Weimann, Christian Bahrs et al. · Deutsches Ärzteblatt international Open access	24 Jan 2019	74
46	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy Frederik Marmé, Bianca Lederer, Jens‐Uwe Blohmer et al. · European Journal of Cancer	13 Dec 2015	72
47	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer Esther Pohl‐Rescigno et al. · JAMA Oncology Open access	12 Mar 2020	67
48	Appendicitis during the COVID-19 lockdown: results of a multicenter analysis in Germany CAMIN Study Group et al. · Langenbeck s Archives of Surgery Open access	7 Feb 2021	65
49	Distal Pancreatectomy in Chronic Pancreatitis M. H. Schoenberg, Wayne D. Schlosser, Wolfgang Rück et al. · Digestive Surgery	1999	64
50	Panta Rhei: Neovascularization, Angiogenesis and Nutritive Perfusion in Wound Healing Heiko Sorg, Daniel J. Tilkorn, Ursula Mirastschijski et al. · European Surgical Research	2018	62

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.